Arene-ruthenium complexes with ferrocene-derived ligands: Synthesis and characterization of complexes of the type [Ru(η6-arene)(NC5H4CH2NHOC-C5H4FeC5H5)Cl2] and [Ru(η6-arene)(NC3H3N(CH2)2O2C-C5H4FeC5H5)Cl2]

被引：47
作者：
Auzias, Mathieu [1 ]
Gueniat, Joeel [1 ]
Therrien, Bruno [1 ]
Suess-Fink, Georg [1 ]
Renfrew, Anna K. [2 ]
Dyson, Paul J. [2 ]
机构：
[1] Univ Neuchatel, Inst Chim, CH-2009 Neuchatel, Switzerland
[2] Ecole Polytech Fed Lausanne, Inst Sci & Ingn Chim, CH-1015 Lausanne, Switzerland
来源：
JOURNAL OF ORGANOMETALLIC CHEMISTRY | 2009年 / 694卷 / 06期
关键词：
Ruthenium; Anticancer agents; Bioorganometallic chemistry; Arene ligands; Ferrocene-derived ligands; ESTROGEN-RECEPTOR MODULATORS; PLASMA-MASS SPECTROMETRY; IN-VITRO; HUMAN SERUM; CAPILLARY-ELECTROPHORESIS; ANTICANCER ACTIVITY; PROTEIN-BINDING; NAMI-A; DNA; CANCER;
D O I：
10.1016/j.jorganchem.2008.08.012
中图分类号：
O61 [无机化学];
学科分类号：
070301 ; 081704 ;
摘要：
Arene-ruthenium complexes of general formula [Ru(eta(6)-arene)(L)Cl-2] where L=NC5H4CH2NHOC-C5H4FeC5H5, arene=p-(PrC6H4Me)-Pr-i (1) or C6Me6 (2); L=NC3H3N(CH2)(2)O2C-C5H4FeC5H5, arene=p-(PrC6H4Me)-Pr-i (3) or C6Me6 (4), and diruthenium-arene complexes of general formula [Ru(eta(6-)arene) Cl-2](2)(L) where L=1,1'-(NC5H4CH2NHOC)(2)-C5H4FeC5H4, arene=p-(PrC6H4Me)-Pr-i (5) or C6Me6 (6); L=1,1'-(NC3H3N(CH2)(2)O2C)(2)-C5H4FeC5H4, arene=p-(PrC6H4Me)-Pr-i (7) or C6Me6 (8) have been synthesized and characterized. The molecular structures of 1 and 3 were confirmed by single-crystal X-ray diffraction. The in vitro anticancer activities of complexes 1-8 have been studied comparatively to the uncoordinated ligands. The complexes exhibit fairly low cytotoxicities in comparison to related ferrocene-derived arene-ruthenium complexes. (C) 2008 Elsevier B. V. All rights reserved.
引用
收藏
页码：855 / 861
页数：7
相关论文
共 52 条
[31]   Inhibition of cancer cell growth by ruthenium(II) arene complexes [J].
Morris, RE ;
Aird, RE ;
Murdoch, PD ;
Chen, HM ;
Cummings, J ;
Hughes, ND ;
Parsons, S ;
Parkin, A ;
Boyd, G ;
Jodrell, DI ;
Sadler, PJ .
JOURNAL OF MEDICINAL CHEMISTRY, 2001, 44 (22) :3616-3621
[32]   Selective estrogen receptor modulators in the ruthenocene series.: Synthesis and biological behavior [J].
Pigeon, P ;
Top, S ;
Vessières, A ;
Huché, M ;
Hillard, EA ;
Salomon, E ;
Jaouen, G .
JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (08) :2814-2821
[33]   Platinum group metallodrug-protein binding studies by capillary electrophoresis - inductively coupled plasma-mass spectrometry: A further insight into the reactivity of a novel antitumor ruthenium(III) complex toward human serum proteins [J].
Polec-Pawlak, K ;
Abramski, JK ;
Semenova, O ;
Hartinger, CG ;
Timerbaev, AR ;
Keppler, BK ;
Jarosz, M .
ELECTROPHORESIS, 2006, 27 (5-6) :1128-1135
[34]   Transferrin binding and transferrin-mediated cellular uptake of the ruthenium coordination compound KP1019, studied by means of AAS, ESI-MS and CD spectroscopy [J].
Pongratz, M ;
Schluga, P ;
Jakupec, MA ;
Arion, VB ;
Hartinger, CG ;
Allmaier, G ;
Keppler, BK .
JOURNAL OF ANALYTICAL ATOMIC SPECTROMETRY, 2004, 19 (01) :46-51
[35]   ANTITUMOR EFFECTS OF BINUCLEAR FERROCENE DERIVATIVES [J].
POPOVA, LV ;
BABIN, VN ;
BELOUSOV, YA ;
NEKRASOV, YS ;
SNEGIREVA, AE ;
BORODINA, NP ;
SHAPOSHNIKOVA, GM ;
BYCHENKO, OB ;
RAEVSKII, PM ;
MOROZOVA, NB ;
ILYINA, AI ;
SHITKOV, KG .
APPLIED ORGANOMETALLIC CHEMISTRY, 1993, 7 (02) :85-94
[36]   Improved understanding in platinum antitumour chemistry [J].
Reedijk, J .
CHEMICAL COMMUNICATIONS, 1996, (07) :801-806
[37]   PLATINUM COMPOUNDS - A NEW CLASS OF POTENT ANTITUMOUR AGENTS [J].
ROSENBERG, B ;
VANCAMP, L ;
TROSKO, JE ;
MANSOUR, VH .
NATURE, 1969, 222 (5191) :385-+
[38]   PREPARATION, CHARACTERIZATION AND ANTILEUKEMIC PROPERTIES OF DIAMINEMALONATOPLATINUM(II) COMPLEXES TETHERED TO FERROCENE [J].
ROSENFELD, A ;
BLUM, J ;
GIBSON, D ;
RAMU, A .
INORGANICA CHIMICA ACTA, 1992, 201 (02) :219-221
[39]  
Sava G, 2003, CLIN CANCER RES, V9, P1898
[40]   Redox behavior of tumor-inhibiting ruthenium(III) complexes and effects of physiological reductants on their binding to GMP [J].
Schluga, P ;
Hartinger, CG ;
Egger, A ;
Reisner, E ;
Galanski, M ;
Jakupec, MA ;
Keppler, BK .
DALTON TRANSACTIONS, 2006, (14) :1796-1802
123456